Adjuvant therapy for small HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have had surgery to remove the breast cancer.
- Your tumor is smaller than 8 mm and has not spread to lymph nodes or other parts of the body.
- Your tumor is HER2-positive (a protein that promotes cancer growth) and has a high nuclear grade (cells look very abnormal).
- You have not had any prior treatment for breast cancer (like chemotherapy or radiation).
- You are generally healthy, with good heart, liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.